Screening and Risk Assessment Overview
24 Questions
0 Views

Screening and Risk Assessment Overview

Created by
@AdventuresomeWichita

Questions and Answers

What is a criteria that may NOT be considered when determining pharmacological treatment for patients?

  • Patient's age
  • Patient's family medical history
  • Patient's dietary preferences (correct)
  • Current health conditions
  • Which of the following medications would NOT typically fall under the category of lipid lowering medications?

  • PCSK9 inhibitors
  • Fibrates
  • Beta-blockers (correct)
  • Statins
  • What is a potential adverse effect of statin therapy that patients must be informed of?

  • Weight gain
  • Muscle weakness (correct)
  • Enhanced cognitive functioning
  • Increased appetite
  • When considering non-statin therapy, which of the following should be taken into account?

    <p>Patient's previous reactions to statins</p> Signup and view all the answers

    In pharmacological treatment, which factor is crucial for effective dosing recommendations?

    <p>Patient's weight and overall health</p> Signup and view all the answers

    What would be considered a common reason for discontinuing statin therapy?

    <p>Achieving target lipid levels</p> Signup and view all the answers

    Which of the following approaches is least likely to be recommended for managing lipid levels in patients?

    <p>Complete avoidance of all fats</p> Signup and view all the answers

    Which factor is least relevant when assessing the need for pharmacological treatment in lipid management?

    <p>Patient's last meal</p> Signup and view all the answers

    What is the primary purpose of the CCS Dyslipidemia Guidelines?

    <p>To offer a practical approach to care for healthcare providers.</p> Signup and view all the answers

    Which statement is true regarding the adherence to the recommendations in the guidelines?

    <p>Adherence does not guarantee successful outcomes in every case.</p> Signup and view all the answers

    What aspect of the guidelines is subject to change?

    <p>Scientific knowledge and technology.</p> Signup and view all the answers

    What does the information about the GRADE approach pertain to?

    <p>Strength of recommendations and quality of evidence.</p> Signup and view all the answers

    Which professionals are intended to use the CCS Dyslipidemia Guidelines?

    <p>Pharmacists, nurses, and healthcare providers.</p> Signup and view all the answers

    How often have the guidelines been revised prior to the 2021 edition?

    <p>Four revisions from 2006 to 2016.</p> Signup and view all the answers

    Who is the co-chair of the CCS Dyslipidemia Guidelines?

    <p>Glen J. Pearson, PharmD FCCS.</p> Signup and view all the answers

    What is the likely impact of adhering to the pharmacological treatment recommendations?

    <p>Potential variability in outcomes based on individual cases.</p> Signup and view all the answers

    Which condition does NOT warrant statin therapy according to the risk management recommendations?

    <p>Age under 50 years with chronic kidney disease</p> Signup and view all the answers

    What is the preferred lipid parameter for screening in risk assessment if not using LDL-C?

    <p>ApoB</p> Signup and view all the answers

    Which of the following patient categories would benefit from statin treatment according to the guidelines?

    <p>Age 50 years with chronic kidney disease</p> Signup and view all the answers

    Which of the following lipid thresholds indicates an urgent need for statin therapy?

    <p>LDL of 5.0 mmol/L</p> Signup and view all the answers

    What is the recommended frequency for repeating screening when assessing cardiovascular risk using the Framingham Risk Score?

    <p>Every 5 years</p> Signup and view all the answers

    Which of the following conditions is associated with a higher risk trigger for statin therapy?

    <p>Atherosclerotic cardiovascular disease (ASCVD)</p> Signup and view all the answers

    Which of the following is NOT indicated for statin initiation based on the recommendations?

    <p>Age 40 with diabetes and no CVD risk factors</p> Signup and view all the answers

    What is the significance of an eGFR of 3 mg/mmol in a patient age 50 years or older?

    <p>It suggests possible chronic kidney disease</p> Signup and view all the answers

    Study Notes

    About the Pocket Guide

    • Provides quick-reference diagnostic and treatment recommendations based on 2021 CCS Dyslipidemia Guidelines.
    • Incorporates unchanged recommendations from previous guidelines (2006, 2009, 2012, 2016).
    • Aims to assist healthcare providers while recognizing that clinical judgment is essential.
    • Recommendations subject to change with evolving scientific knowledge and practices.

    Screening

    • Determine who to screen and the method for screening dyslipidemia.
    • Use the Framingham Risk Score (FRS) or Cardiovascular Life Expectancy Model (CLEM) for risk assessment unless a statin-indicated condition exists.
    • Recommended to repeat screening every 5 years for certain lipid parameters.
    • Prefer non-HDL-C or ApoB over LDL-C for screening based on strong recommendations and high-quality evidence.

    Risk Assessment

    • Important for primary prevention strategies and identifying high-risk patients.
    • LDL ≥5.0 mmol/L or ApoB ≥1.45 g/L indicates a need for statin therapy.
    • Key demographic factors for considering pharmacological treatment include age and diabetes status.

    Management

    • Statin therapy recommended for high-risk conditions such as:
      • Clinical atherosclerosis and abdominal aortic aneurysm.
      • Most patients with diabetes, particularly those aged ≥40 years or with diabetes for ≥15 years.
      • Chronic kidney disease in patients aged ≥50 years.
    • Additional statin indications include persistent elevated LDL-C (≥5.0 mmol/L) and significant atherosclerotic cardiovascular disease (ASCVD).
    • Management should focus on lowering cardiovascular disease (CVD) events and mortality risk.
    • Adverse effects and considerations for non-statin therapy should be acknowledged in treatment plans.

    Key Stats and Terms

    • TIA: Transient ischemic attack.
    • ABI: Ankle-brachial index.
    • ACR: Albumin:creatinine ratio.
    • eGFR: Estimated glomerular filtration rate.

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Description

    This quiz covers essential aspects of screening and risk assessment for primary prevention. It focuses on identifying who should be screened and the methods of screening, along with the importance of secondary testing. Prepare to explore these vital concepts in public health.

    More Quizzes Like This

    Trisomie 21 Screening Methods
    20 questions

    Trisomie 21 Screening Methods

    CredibleJuxtaposition avatar
    CredibleJuxtaposition
    Biomolecular Screening Methods Quiz
    12 questions
    Antibody Screening Methods
    8 questions
    Use Quizgecko on...
    Browser
    Browser